Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival
Authors
Keywords
-
Journal
OncoImmunology
Volume -, Issue -, Pages 1-15
Publisher
Informa UK Limited
Online
2018-09-12
DOI
10.1080/2162402x.2018.1509820
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune Infiltration in Invasive Lobular Breast Cancer
- (2018) Christine Desmedt et al. JNCI-Journal of the National Cancer Institute
- Immune Infiltration in Invasive Lobular Breast Cancer
- (2018) Christine Desmedt et al. JNCI-Journal of the National Cancer Institute
- Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients
- (2017) Gerardo Botti et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer
- (2017) António Polónia et al. JOURNAL OF CLINICAL PATHOLOGY
- Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non–Small Cell Lung Cancer
- (2017) Chao Li et al. Journal of Thoracic Oncology
- Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
- (2017) Samra Turajlic et al. LANCET ONCOLOGY
- PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast
- (2017) Elizabeth D Thompson et al. MODERN PATHOLOGY
- Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
- (2017) Riccardo Mezzadra et al. NATURE
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Combined immune checkpoint blockade as a therapeutic strategy for BRCA1 -mutated breast cancer
- (2017) Emma Nolan et al. Science Translational Medicine
- The genomic landscape of breast cancer and its interaction with host immunity
- (2016) Stephen Luen et al. BREAST
- Equivalence of MammaPrint array types in clinical trials and diagnostics
- (2016) Inès Beumer et al. BREAST CANCER RESEARCH AND TREATMENT
- The immune system and hormone-receptor positive breast cancer: Is it really a dead end?
- (2016) Maria Vittoria Dieci et al. CANCER TREATMENT REVIEWS
- Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer
- (2016) In Hae Park et al. Clinical Breast Cancer
- Targeting the programmed cell death-1 pathway in breast and ovarian cancer
- (2016) Leisha A. Emens et al. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
- Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome
- (2016) Rhiannon K Beckers et al. HISTOPATHOLOGY
- PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
- (2016) Ashley Cimino-Mathews et al. HUMAN PATHOLOGY
- Prognostic significance of PD-L1 and PD-L2 in breast cancer
- (2016) Mauricio Z. Baptista et al. HUMAN PATHOLOGY
- Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer
- (2016) Jamaal A Rehman et al. MODERN PATHOLOGY
- 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
- (2016) Fatima Cardoso et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 expression in human cancers and its association with clinical outcomes
- (2016) Jinming Yu et al. OncoTargets and Therapy
- Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration
- (2016) Marcel Smid et al. Nature Communications
- Concepts and targets in triple-negative breast cancer: recent results and clinical implications
- (2016) Poornima Saha et al. Therapeutic Advances in Medical Oncology
- Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer
- (2016) Laurence Buisseret et al. OncoImmunology
- PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker
- (2016) Lei Guo et al. SpringerPlus
- Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer
- (2016) Magali Michaut et al. Scientific Reports
- Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab
- (2015) Hee Jin Lee et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes
- (2015) H. R. Ali et al. ANNALS OF ONCOLOGY
- BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential
- (2015) Tesa M. Severson et al. Molecular Oncology
- Clinical relevance of host immunity in breast cancer: from TILs to the clinic
- (2015) Peter Savas et al. Nature Reviews Clinical Oncology
- High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer
- (2015) Tao Qin et al. Oncotarget
- Prognostic and predictive value of PDL1 expression in breast cancer
- (2015) Renaud Sabatier et al. Oncotarget
- PD-L1 and Survival in Solid Tumors: A Meta-Analysis
- (2015) Pin Wu et al. PLoS One
- Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients
- (2014) H. R. Ali et al. ANNALS OF ONCOLOGY
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
- (2014) S. Muenst et al. BREAST CANCER RESEARCH AND TREATMENT
- In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
- (2014) K. A. Schalper et al. CLINICAL CANCER RESEARCH
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- MammaPrint Molecular Diagnostics on Formalin-Fixed, Paraffin-Embedded Tissue
- (2014) Anna Sapino et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+tumor infiltrating lymphocytes in ductal and lobular breast cancers
- (2012) Raoul Droeser et al. BMC CANCER
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response
- (2011) Oscar Krijgsman et al. BREAST CANCER RESEARCH AND TREATMENT
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- ONCOPOOL – A European database for 16,944 cases of breast cancer
- (2009) R.W. Blamey et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started